Zevra expects to meet with the FDA at the end of the third quarter to discuss the design of a phase 3 trial for KP1077 in idiopathic hypersomnia.
Summary: Zevra Therapeutics provided updates for the second quarter of 2024, highlighting progress in advancing KP1077 for idiopathic hypersomnia. The company presented positive phase 2 data at the SLEEP 2024 meeting, showing that KP1077 was well tolerated and demonstrated early signs of clinical benefit. Zevra plans to meet with the FDA at the end of Q3 2024 to discuss the design of a pivotal phase 3 trial.
Key Takeaways:
- Positive Phase 2 Data: Zevra presented results from its phase 2 study of KP1077 in idiopathic hypersomnia during the quarter, showing the drug was well tolerated and exhibited early signs of clinical benefit.
- Upcoming FDA Meeting: Zevra is preparing to meet with the FDA at the end of Q3 2024 to discuss the design of a phase 3 trial for KP1077.
- Increased R&D Investment: The company reported an increase in research and development expenses in Q2 2024, primarily due to the ongoing phase 2 clinical trial for KP1077.
Zevra Therapeutics Inc, a rare disease therapeutics company, provided financial results and corporate updates for the second quarter ended June 30, including ongoing efforts to advance KP1077 for idiopathic hypersomnia.
On June 3, Zevra presented positive topline data from its phase 2 study in patients with idiopathic hypersomnia at the SLEEP 2024 annual meeting. The placebo-controlled, double-blind, proof-of-concept study showed that KP1077 was well tolerated and demonstrated early signs of potentially differentiated and clinically meaningful benefits.
The company submitted a briefing book to the US Food and Drug Administration (FDA) for an end-of-phase 2 meeting to be held at the end of Q3 2024. The company expects to meet with the FDA to discuss the design of a pivotal phase 3 trial to study KP1077 in idiopathic hypersomnia.
“During the second quarter, we made steady progress executing on our strategic objectives,” says Neil F. McFarlane, president and chief executive officer of Zevra, in a release.
Net revenue for Q2 2024 was $4.4 million, compared to net revenue of $8.5 million in Q2 2023. Research and development expenses were $10.5 million for Q2 2024, compared to $7.4 million in Q2 2023. The increase in research and development expenses was driven primarily by an increase in spending for the KP1077 phase 2 clinical trial and an increase in personnel-related costs, partially offset by a decrease in third-party costs related to arimoclomol, a treatment in development for patients with Niemann Pick disease type C.
